![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a600034 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | ~96% |
Metabolism | Hepatic (CYP3A4)[1] |
Elimination half-life | 24 hours |
Excretion | Fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.065.837 |
Chemical and physical data | |
Formula | C28H31FN4O |
Molar mass | 458.581 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Astemizole (marketed under the brand name Hismanal, developmental code R43512) was a second-generation antihistamine drug that has a long duration of action. Astemizole was discovered by Janssen Pharmaceutica in 1977. It was withdrawn from the market globally in 1999 because of rare but potentially fatal side effects (QTc interval prolongation and related arrhythmias due to hERG channel blockade).[2][3]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search